← Eichor
Study identifier: NCT07703345 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Salivary Apelin, Chemerin, Ghrelin, and Lipocalin-2 Levels in Diabetic Patients With Periodontitis

Condition: Periodontitis · Type 2 Diabetes Mellitus (T2DM)  ·  Sponsor: Necmettin Erbakan University

PhaseN/A
Planned participants88
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersYes

About this study

This observational cross-sectional study will evaluate salivary apelin, chemerin, ghrelin, and lipocalin-2 levels in individuals with different periodontal and systemic conditions. Participants will be divided into four groups according to periodontal status and the presence or absence of type 2 diabetes mellitus. Clinical periodontal measurements and unstimulated saliva samples will be obtained before periodontal treatment. Salivary biomarker levels will be measured using enzyme-linked immunosorbent assay kits. The study aims to determine whether salivary apelin, chemerin, ghrelin, and lipocalin-2 levels are associated with periodontitis, type 2 diabetes mellitus, and periodontal clinical parameters.

This description comes directly from the study's public registry record.

Talk to the study team

Osman Babayiğit  ·  +90 506 320 84 74  ·  obabayigit@erbakan.edu.tr

Always discuss trial participation with your own doctor first.

Locations (1)

Necmettin Erbakan University Faculty of Dentistry, Department of PeriodontologyKonya, Konya, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07703345